Ultragenyx Pharmaceutical (RARE) Competitors $31.76 -0.27 (-0.84%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. QGEN, MRNA, VRNA, BBIO, ELAN, ROIV, GRFS, RVMD, RYTM, and LEGNShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Qiagen (QGEN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors Qiagen Moderna Verona Pharma PLC American Depositary Share BridgeBio Pharma Elanco Animal Health Roivant Sciences Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Ultragenyx Pharmaceutical (NASDAQ:RARE) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Does the media prefer RARE or QGEN? In the previous week, Qiagen had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 24 mentions for Qiagen and 12 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.39 beat Qiagen's score of 0.96 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RARE or QGEN? Ultragenyx Pharmaceutical currently has a consensus target price of $81.50, indicating a potential upside of 156.60%. Qiagen has a consensus target price of $49.69, indicating a potential upside of 6.10%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 Is RARE or QGEN more profitable? Qiagen has a net margin of 18.30% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. Qiagen's return on equity of 14.77% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-87.34% -237.48% -37.66% Qiagen 18.30%14.77%8.87% Which has more risk & volatility, RARE or QGEN? Ultragenyx Pharmaceutical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Which has higher earnings & valuation, RARE or QGEN? Qiagen has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$610.16M5.02-$569.18M-$5.53-5.74Qiagen$1.98B5.26$83.59M$1.6927.71 Do insiders & institutionals believe in RARE or QGEN? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryQiagen beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06B$3.09B$5.73B$9.81BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-5.7421.0582.3826.51Price / Sales5.02388.53526.77107.89Price / CashN/A43.5325.7028.92Price / Book20.238.0810.636.55Net Income-$569.18M-$53.35M$3.28B$266.04M7 Day Performance5.59%-0.15%-0.35%-0.79%1 Month Performance11.68%9.24%9.99%6.02%1 Year Performance-42.99%10.70%48.79%21.97% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.5088 of 5 stars$31.76-0.8%$81.50+156.6%-43.6%$3.06B$610.16M-5.741,294Positive NewsQGENQiagen4.1864 of 5 stars$48.92-1.6%$49.69+1.6%+5.6%$10.87B$1.98B28.905,765News CoveragePositive NewsMRNAModerna4.5587 of 5 stars$25.35-6.5%$42.88+69.2%-68.7%$9.86B$3.24B-3.375,800VRNAVerona Pharma PLC American Depositary Share2.3763 of 5 stars$105.62+0.1%$109.00+3.2%+286.1%$9.14B$42.28M-106.6930News CoveragePositive NewsBBIOBridgeBio Pharma4.168 of 5 stars$47.29-3.6%$61.35+29.7%+79.5%$9.04B$221.90M-11.56400News CoverageAnalyst ForecastELANElanco Animal Health3.093 of 5 stars$17.80-0.6%$17.33-2.6%+15.5%$8.84B$4.44B20.709,000Analyst RevisionROIVRoivant Sciences3.1694 of 5 stars$11.64-2.3%$16.50+41.8%+1.3%$7.95B$29.05M-16.63860News CoveragePositive NewsAnalyst ForecastGRFSGrifols3.9345 of 5 stars$9.82-3.3%$10.30+4.9%+3.6%$6.75B$7.45B8.3923,822News CoveragePositive NewsRVMDRevolution Medicines4.4743 of 5 stars$35.67-3.6%$69.92+96.0%-7.3%$6.67B$11.58M-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.3008 of 5 stars$99.20-3.9%$101.57+2.4%+120.4%$6.59B$156.29M-32.96140News CoveragePositive NewsLEGNLegend Biotech3.5372 of 5 stars$34.60-2.7%$73.00+111.0%-40.5%$6.36B$627.24M-39.322,609 Related Companies and Tools Related Companies Qiagen Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Grifols Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts